Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.
about
Cytomegalovirus infection in transplant recipientsThe pros and the cons of mTOR inhibitors in kidney transplantation.mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.Release of human cytomegalovirus from latency by a KAP1/TRIM28 phosphorylation switchA 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic riskTuberous Sclerosis Complex Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38.Minimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015?Treatment of cytomegalovirus infections beyond acute disease to improve human health.Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?Everolimus and sirolimus in transplantation-related but different.Prolonged norovirus infection after pancreas transplantation: a case report and review of chronic norovirus.Safety of mTOR inhibitors in adult solid organ transplantation.Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.Conversion From Sirolimus to Everolimus in Long-Term Liver Graft Recipients.Norovirus infection in primary immune deficiency.Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.Infectious Complications Following Small Bowel Transplantation.Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.How immunosuppressive therapy affects T cells from kidney transplanted patients of different age: the role of latent cytomegalovirus infection.Everolimus-associated stomatitis in a patient who had renal transplant.
P2860
Q26801802-1EB1BC33-8994-4421-B348-A15B46CAB71DQ33412367-8BBF7B49-06ED-46EE-8335-583BBDA8B345Q33424013-450F5F08-A0AB-47EA-840F-3BF4AB48FF1FQ35260579-263997AD-E3C7-4F51-80BC-AE703327F9E4Q35649082-059E3FAB-933E-454B-9B55-176681E9FE6FQ35861166-54C6A08C-EE6F-482A-AF99-1C3CFC61F1BFQ36087779-3227A14F-FEFB-42C3-A0A3-DABAD4352B92Q38176940-91D217EC-8019-4E47-8346-DE0B09EA3C7BQ38190678-1D4D83F4-A55F-444F-9461-7F4EE69B8B15Q38442560-CB5AC186-96B7-45F1-8BB2-EE43B85183DFQ38605836-389F714D-DE74-4E74-BA99-278B0573B96BQ38669190-90D04307-329F-4002-9F99-1763A2EAC05DQ38947867-DA31CAFB-8E9D-4A45-B186-B9BF8FA90396Q38992157-7DE0A1B3-3820-469D-BDA2-915A7FBD71DDQ39167685-99500F75-A48C-4A03-99A2-45334EBC3394Q40134753-A049E480-F8BD-47EC-ADA7-9A271E527E42Q40267366-4A90FE73-14AD-440E-9AF9-2BC4B8BF02C6Q40483831-6CC243C1-DE99-4D97-AA16-47BAE26A81BAQ40856064-3F9A9704-99ED-47C8-9B48-17401470C382Q40912977-26DE2B9F-8E54-4548-9D0A-2F97A445F9C0Q41218897-F98FCA64-06E7-4CA8-ABF6-4A64EF67D64FQ42270266-1E966CE0-8CD0-48F6-B3AE-1563FCF798F3Q48261908-4AEE7A52-E095-47D5-B466-73CEB16E4338
P2860
Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Is cytomegalovirus prophylaxis ...... atic review and meta-analysis.
@en
type
label
Is cytomegalovirus prophylaxis ...... atic review and meta-analysis.
@en
prefLabel
Is cytomegalovirus prophylaxis ...... atic review and meta-analysis.
@en
P2093
P1433
P1476
Is cytomegalovirus prophylaxis ...... atic review and meta-analysis.
@en
P2093
Antje Habicht
Bruno Meiser
Joachim Andrassy
Karl-Walter Jauch
Manfred Stangl
Markus Guba
Markus Rentsch
Michael Fischereder
Verena S Hoffmann
P304
P356
10.1097/TP.0B013E3182708E56
P577
2012-12-01T00:00:00Z